Di- and trinuclear Ru(II) complexes of 1,10-phenanthroline and 2,2′-bipyridine derivatives; synthesis, photophysical and electrochemical properties

MLCT Excited-State Behavior of Trinuclear Ruthenium(II) 2,2'-Bipyridine Complexes

Four trinuclear ruthenium(II) polypyridyl complexes were synthesized, and a detailed investigation of their excited-state properties was performed. The tritopic sexi-pyridine bridging ligands were obtained via para or meta substitution of a central 2,2'-bipyridine fragment. A para connection between the 2,2'-bipyridine chelating moieties of the bridging ligand led to a red-shifted MLCT absorption band in the visible part of the spectra, whereas the meta connection induced a broadening of the LC transitions in the UV region. A convergent energy transfer from the two peripheral metal centers to the central Ru(II) moiety was observed for all trinuclear complexes. These complexes were in thermal equilibrium with an upper-lying ³MLCT excited state over the investigated range of temperatures. For all complexes, deactivation via the ³MC excited state was absent at room temperature. Importantly, the connection in the para position for both central and peripheral 2,2'-bipyridines of the bridging ligand resulted in a trinuclear complex (T_pp) that absorbed more visible light, had a longer-lived excited state, and had a higher photoluminescence quantum yield than the parent [Ru(bpy)₃]²⁺, despite its red-shifted photoluminescence. This behavior was attributed to the presence of a highly delocalized excited state for T_pp.

A Ru(II) polypyridyl complex bearing aldehyde functions as a versatile synthetic precursor for long-wavelength absorbing photodynamic therapy photosensitizers

The use of Photodynamic Therapy (PDT) for the treatment of several kinds of cancer as well as bacterial, fungal or viral infections has received increasing attention during the last decade. However, the currently clinically approved photosensitizers (PSs) have several drawbacks, including photobleaching, slow clearance from the organism and poor water solubility. To overcome these shortcomings, many efforts have been made in the development of new types of PSs, such as Ru(II) polypyridyl complexes. Nevertheless, most studied Ru(II) polypyridyl complexes have a low absorbance in the spectral therapeutic window. In this work, we show that, by carefully selecting substituents on the polypyridyl complex, it is possible to prepare a complex absorbing at a much higher wavelength. Specifically, we report on the synthesis as well as in-depth experimental and theoretical characterisation of a Ru(II) polypyridyl complex (complex 3) combining a shift in absorbance towards the spectral therapeutic window with a high ¹O₂ production. To overcome the absence or poor selectivity of most approved PSs into targeted cells/bacteria, they can be linked to targeting moieties. In this line, compound 3 was designed with reactive aldehyde groups, which can be used as a highly versatile synthetic precursor for further conjugation. As a proof of concept, 3 was reacted with benzylamine and the stability of the resulting conjugate 4 was investigated in DMSO, PBS and cell media. 4 showed an impressive ability to act as a PDT PS with no measurable dark cytotoxicity and photocytotoxicity in the low micromolar range against cancerous HeLa cells from 450 nm up to 540 nm.